Runnymede Capital Advisors’s AbbVie ABBV Stock Holding History

Runnymede Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Buy	4,581 +1,081	+31%	+$233K	0.69%	23
2026 Q1	$761K	Buy	+3,500	New	+$776K	0.65%	30
2025 Q4	–	Sell	-3,500	Closed	-$810K	–	75
2025 Q3	$810K	Hold	3,500	–	–	0.67%	27
2025 Q2	$650K	Hold	3,500	–	–	0.6%	32
2025 Q1	$733K	Hold	3,500	–	–	0.7%	28
2024 Q4	$622K	Buy	+3,500	New	+$643K	0.54%	31

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Runnymede Capital Advisors's ABBV Position: Q2 2026 in Review

Runnymede Capital Advisors increased its AbbVie (ABBV) stake by 31% in Q2 2026, buying an estimated $233K and bringing the position to 4,581 shares worth $1.15M. The position accounts for 0.69% of the portfolio, ranked #23.

Runnymede Capital Advisors first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. 1,174 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Runnymede Capital Advisors held 4,581 shares of AbbVie worth $1.15M as of Q2 2026.
Runnymede Capital Advisors bought 1,081 AbbVie shares in Q2 2026, an estimated $233K.
AbbVie made up 0.69% of Runnymede Capital Advisors's portfolio in Q2 2026, its #23 holding.
Runnymede Capital Advisors first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
1,174 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Runnymede Capital Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.